Inventiva achieves a major milestone by completing patient recruitment for its Phase IIb clinical study with lanifibranor in NASH

    NEXT STORY
    Oasmia completes its management team
    PREV STORY
    More former foster youth could succeed in school with $150,000 investment from United Way of the Lower Mainland
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting

    author_avatar
    NASDAQ Market News

    Precision Therapeutics to Hold Business Update Conference Call on August 14, 2018

    MINNEAPOLIS, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or ...

    author_avatar
    NASDAQ Market News

    Precision Therapeutics Forms Scientific Advisory Board to Advance its Strategy in the Precision Medicine Sector

    Marc Malandro PhD Named First Member of Scientific Advisory BoardMINNEAPOLIS , Sept. 06, 2018 ...

    author_avatar
    NASDAQ Market News